With the aid of our advanced platform and extensive experience in tumor marker assay discovery, Creative Biolabs specializes in engineering neuroblastoma cells for self-destruction purposes, which will help our customers to meet research needs.
Neuroblastoma (NB) is an extremely aggressive and malignant solid tumor in children, accounting for 7% of tumors in children under 15 years old and 15% of child deaths due to cancers. It is the second most common solid tumor in children after CNS tumors and presents the third type after brain tumors and leukemia regarding the incidence of childhood cancers. Neuroblastoma is a complex tumor with unique characteristics. The biological heterogeneity of neuroblastoma contributes to the various clinical manifestations of this cancer. In some patients, neuroblastoma may completely regress or differentiate spontaneously, with complete recovery without any treatment. While in other cases, children with neuroblastoma develop extensive metastatic tumors with poor prognosis.
Over the past decades, there are various clinical trials of new targeted agents have been launched. The available targeted therapies for neuroblastoma mainly include therapies targeting genetic aberrations; therapies targeting disrupted signaling molecules; immunology-based approaches; radio-drug targeting of norepinephrine and somatostatin receptors; therapies targeting epigenetic regulators; and therapies targeting Bcl-2 family proteins. In these strategies, immunology-based approaches have played an effective role. Anti-GD2 mAb ch14.18 is the first FDA-approved drug for high-risk neuroblastoma in nearly 30 years and represents a breakthrough in the treatment of neuroblastoma. As the most promising drug for the treatment of neuroblastoma, anti-GD2 mAb has presented remarkable anti-tumor activity and greatly improved the survival rate of neuroblastoma children in widespread administration. In addition, the development of CAR-T therapy in neuroblastoma is also a hot topic of current research.
Fig.1 Targeted therapy in neuroblastoma. (Zafar, et al., 2021)
Taking advantage of advanced technology platforms and deep scientific and regulatory understanding in immune-oncology, Creative Biolabs specializes in engineering neuroblastoma cells for self-destruction purposes for our global clients to speed up neuroblastoma research.
Engineering neuroblastoma cells for self-destruction portfolio services are MOA-reflective.
Highly reproducible assays for potency for therapeutics discovery and development.
From initial design and optimization all the way down to preclinical study with well-recorded data and organized reports.
What is more, Creative Biolabs is dedicated to offering the following cancer research topic including but not limited to:
If there is any query, please contact us for more details.
References
For Research Use Only | Not For Clinical Use
Download our brochure